发明名称 |
Controlled release compositions containing zolpidem |
摘要 |
The present invention relates to controlled release compositions of Zolpidem or pharmaceutically acceptable salts thereof adapted to release Zolpidem over a predetermined time period, according to a monophasic and/or a biphasic profile of dissolution. The present invention also relates to monolithic matrix based formulations of Zolpidem or pharmaceutically acceptable salts thereof. |
申请公布号 |
US8846084(B2) |
申请公布日期 |
2014.09.30 |
申请号 |
US200611991361 |
申请日期 |
2006.12.15 |
申请人 |
Wockhardt Ltd |
发明人 |
Mandaogade Prashant Manohar;Joshi Venkatesh Madhavacharya;Jain Girish Kumar |
分类号 |
A61K9/22;A61K9/26;A61K31/44;A61K9/20;A61K9/50;A61K9/24 |
主分类号 |
A61K9/22 |
代理机构 |
Bio Intellectual Property Services LLC (Bio IPS) |
代理人 |
Bio Intellectual Property Services LLC (Bio IPS) ;Zaghmout O. (Sam) |
主权项 |
1. A dry granulated pharmaceutical dosage form comprising a polymer matrix, wherein said polymer matrix comprises zolpidem or a pharmaceutically acceptable salt thereof, one or more rate controlling polymers, and one or more pharmaceutically acceptable excipients, wherein the dosage form is adapted to release zolpidem or a salt thereof on a continuous basis over a predetermined time period, according to an in vitro profile of dissolution when measured in a type II dissolution apparatus according to U.S. Pharmacopoeia in 0.01 M hydrochloric acid buffer at 37° C. , wherein less than 40% of the total amount of zolpidem is released between 15 to 30 minutes and the time for release of 90% of the total amount of zolpidem is between 2 to 6 hours; and wherein the dosages form is a controlled release pharmaceutical composition. |
地址 |
Bandra-Kurla Complex, Bandra East, Mumbai IN |